Topic: Targeted Therapy for Liver Cancer
A Special Topic of Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)
Submission deadline: 30 May 2020
Guest Editor
Shu-Kui Qin, MD, PhD
Deputy Director of People's Liberation Army (PLA) 81 Hospital, Nanjing, Jiangsu, China.
Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital; Executive Member of the Asian Clinical Oncology Society (ACOS), and Chair of Chinese Society of Clinical Oncology (CSCO).
Director of Cancer Center of Chinese PLA, and Director of National Drug Clinical Trial Agency of PLA 81 Hospital; Executive Member of the Asian Clinical Oncology Society (ACOS), and Chair of Chinese Society of Clinical Oncology (CSCO).
Special Topic Introduction
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths globally due, in part, to the majority of patients diagnosed with intermediate or advanced stage disease. Our increased understanding of the heterogeneous molecular pathogenesis of HCC has led to significant developments in novel targeted therapies. Despite these advances, there remains a high unmet need for new treatment options.
Submission Deadline
30 May 2020
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/hr/author_instructions
For Online Submission, please login at https://www.oaecenter.com/login?JournalId=hr&IssueId=hr200530328
Submission Deadline: 30 May 2020
Contacts: Haidi Ding, Assistant Editor, [email protected]
